	US 12,440,531 B2
	Composition for use in improving endothelial function by enhancing flow mediated dilation
Lucas Actis Goretta, Singapore (SG); and Rachid Bel-Rhlid, Savigny (CH)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Appl. No. 17/602,052
Filed by SOCIETE DES PRODUITS NESTLE S.A., Vevey (CH)
PCT Filed Apr. 8, 2020, PCT No. PCT/EP2020/060092 § 371(c)(1), (2) Date Oct. 7, 2021, PCT Pub. No. WO2020/208108, PCT Pub. Date Oct. 15, 2020.
Claims priority of application No. 19168455 (EP), filed on Apr. 10, 2019.
Prior Publication US 2022/0193172 A1, Jun. 23, 2022
Int. Cl. A61K 36/74 (2006.01); A23L 33/105 (2016.01); A61P 3/10 (2006.01); A61P 9/08 (2006.01)

CPC A61K 36/74 (2013.01) [A23L 33/105 (2016.08); A61P 3/10 (2018.01); A61K 2236/10 (2013.01); A61K 2236/51 (2013.01)]

12 Claims

1. A method for improving cardiovascular flow and reducing the risk of cardiovascular diseases in healthy subjects as measured by changes in measured flow mediated dilation (FMD) in a subject, wherein the subject is administered an effective dose of a composition comprising esterase treated decaffeinated green coffee extract (HDGCE) in an amount of 100-400 mg/day.